Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 8 studies | 27% ± 9% | |
oligodendrocyte | 7 studies | 27% ± 8% | |
microglial cell | 6 studies | 23% ± 6% | |
GABAergic neuron | 6 studies | 35% ± 16% | |
astrocyte | 6 studies | 33% ± 12% | |
glutamatergic neuron | 5 studies | 46% ± 21% | |
macrophage | 5 studies | 24% ± 9% | |
interneuron | 5 studies | 33% ± 20% | |
oligodendrocyte precursor cell | 4 studies | 27% ± 8% | |
epithelial cell | 3 studies | 27% ± 7% | |
transit amplifying cell | 3 studies | 33% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 99% | 323.24 | 1435 / 1445 | 99% | 6.33 | 182 / 183 |
stomach | 99% | 259.43 | 356 / 359 | 97% | 4.25 | 277 / 286 |
lung | 100% | 415.71 | 578 / 578 | 96% | 4.01 | 1109 / 1155 |
intestine | 100% | 368.13 | 965 / 966 | 94% | 3.24 | 493 / 527 |
breast | 100% | 489.03 | 459 / 459 | 92% | 6.37 | 1023 / 1118 |
pancreas | 98% | 218.93 | 323 / 328 | 84% | 2.22 | 149 / 178 |
skin | 100% | 550.29 | 1805 / 1809 | 81% | 2.97 | 383 / 472 |
uterus | 100% | 414.51 | 170 / 170 | 79% | 3.01 | 364 / 459 |
prostate | 100% | 331.02 | 245 / 245 | 79% | 2.76 | 395 / 502 |
ovary | 100% | 740.19 | 180 / 180 | 77% | 2.18 | 333 / 430 |
bladder | 100% | 407.24 | 21 / 21 | 73% | 2.36 | 370 / 504 |
brain | 84% | 197.88 | 2213 / 2642 | 89% | 3.20 | 630 / 705 |
thymus | 100% | 394.19 | 651 / 653 | 72% | 2.27 | 435 / 605 |
kidney | 98% | 211.96 | 87 / 89 | 72% | 2.85 | 652 / 901 |
adrenal gland | 100% | 378.34 | 258 / 258 | 45% | 1.05 | 103 / 230 |
liver | 97% | 204.37 | 219 / 226 | 46% | 1.03 | 186 / 406 |
adipose | 100% | 506.11 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 404.43 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 315.03 | 799 / 803 | 0% | 0 | 0 / 0 |
spleen | 99% | 260.16 | 239 / 241 | 0% | 0 | 0 / 0 |
heart | 89% | 201.56 | 769 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 82% | 6.06 | 37 / 45 |
peripheral blood | 72% | 461.43 | 669 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 55% | 1.92 | 16 / 29 |
eye | 0% | 0 | 0 / 0 | 39% | 0.68 | 31 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0071108 | Biological process | protein K48-linked deubiquitination |
GO_0051301 | Biological process | cell division |
GO_0035871 | Biological process | protein K11-linked deubiquitination |
GO_0006508 | Biological process | proteolysis |
GO_0006275 | Biological process | regulation of DNA replication |
GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
GO_0016579 | Biological process | protein deubiquitination |
GO_0005694 | Cellular component | chromosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0019901 | Molecular function | protein kinase binding |
GO_0004197 | Molecular function | cysteine-type endopeptidase activity |
GO_0005515 | Molecular function | protein binding |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
Gene name | USP37 |
Protein name | Ubiquitin carboxyl-terminal hydrolase 37 (EC 3.4.19.12) (Deubiquitinating enzyme 37) (Ubiquitin thioesterase 37) (Ubiquitin-specific-processing protease 37) ubiquitinyl hydrolase 1 (EC 3.4.19.12) |
Synonyms | KIAA1594 |
Description | FUNCTION: Deubiquitinase that plays a role in different processes including cell cycle regulation, DNA replication or DNA damage response . Antagonizes the anaphase-promoting complex (APC/C) during G1/S transition by mediating deubiquitination of cyclin-A (CCNA1 and CCNA2), thereby promoting S phase entry. Specifically mediates deubiquitination of 'Lys-11'-linked polyubiquitin chains, a specific ubiquitin-linkage type mediated by the APC/C complex. Phosphorylation at Ser-628 during G1/S phase maximizes the deubiquitinase activity, leading to prevent degradation of cyclin-A (CCNA1 and CCNA2) . Plays an important role in the regulation of DNA replication by stabilizing the licensing factor CDT1 . Plays also an essential role beyond S-phase entry to promote the efficiency and fidelity of replication by deubiquitinating checkpoint kinase 1/CHK1, promoting its stability . Sustains the DNA damage response (DDR) by deubiquitinating and stabilizing the ATP-dependent DNA helicase BLM . Mechanistically, DNA double-strand breaks (DSB) promotes ATM-mediated phosphorylation of USP37 and enhances the binding between USP37 and BLM . Promotes cell migration by deubiquitinating and stabilizing the epithelial-mesenchymal transition (EMT)-inducing transcription factor SNAI . Plays a role in the regulation of mitotic spindle assembly and mitotic progression by associating with chromatin-associated WAPL and stabilizing it through deubiquitination . . |
Accessions | ENST00000415516.5 [Q86T82-2] ENST00000418019.5 [Q86T82-1] Q86T82 ENST00000258399.8 [Q86T82-1] ENST00000454775.5 [Q86T82-1] Q86W68 ENST00000338465.5 |